Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Focal Onset Seizures: full-pipeline trial registry
3 of 5 indexed Focal Onset Seizures trials are currently recruiting.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Focal Onset Seizures: 5 US clinical trials tracked, 3 recruiting.
Focal Onset Seizures is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Xenon Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition focal-onset-seizures
OPEN 3 | RECR 60% | LATE 2 | EARLY 3 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)
Focal Onset Seizures lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Focal Onset Seizures on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Focal Onset Seizures is recruiting above its size-band peers.
3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Focal Onset Seizures research.
Xenon Pharmaceuticals accounts for 2 of 5 trials (40%). 3 distinct sponsors appear on at least one study for this condition label.
-
Typical Focal Onset Seizures enrolment sits around 258 participants.
Median target enrolment is 258 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.
-
Focal Onset Seizures research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Xenon Pharmaceuticals
NCT05716100
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures
Supernus Pharmaceuticals
NCT06798896
SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
Supernus Pharmaceuticals
NCT07141329
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
Xenon Pharmaceuticals
NCT05614063
Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
Rapport Therapeutics
NCT06377930
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Focal Onset Seizures records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Focal Onset Seizures trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Focal Onset Seizures page
5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Focal Onset Seizures trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Xenon Pharmaceuticals sponsors the most Focal Onset Seizures trials on record, review their full trial history before evaluating a specific study. See Xenon Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Focal Onset Seizures condition card totals 5 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.